Werner Cautreels, CEO of Selecta Biosciences, explains that the company is developing next-generation nanoparticle-based vaccines and immunotherapeutics to address autoimmune diseases of high unmet need such as type 1 diabetes, life-threatening allergies, and organ transplant rejection

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…